(RTTNews) - Edwards Lifesciences Corp. (EW) will host a conference call at 5:00 PM ET on November 4, 2026, to discuss Q3 26 earnings results.

Edwards Lifesciences Q3 26 Earnings Conference Call At 5:00 PM ET 

(RTTNews) - Edwards Lifesciences (EW) reported positive results from its CLASP II TR trial, showing that the PASCAL transcatheter valve repair system outperformed medical therapy alone in patients with tricuspid regurgitation, a heart valve condition that causes blood to flow bac

Edwards' PASCAL System Improves Outcomes And Quality Of Life In Tricuspid Valve Disease Trial 

(RTTNews) - Edwards Lifesciences (EW) reported Phase 3 PROGRESS trial results showing that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in patients with moderate aortic stenosis who had features associated with a higher risk of disease progr

Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial 

Key PointsMedtronic recently completed a key spinoff of its diabetes segment.

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?

West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.

Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation News